
	Where results make sense

Topic: Nimodipine

Related Topics

Nifedipine

Vasospasm

Bioavailability

Subarachnoid hemorrhage

Pharmacokinetics

Pulmonary edema

Neurosurgery

Cerebral hemorrhage

	MedlinePlus Drug Information: Nimodipine
		Nimodipine is used to treat symptoms resulting from a ruptured blood vessel in the brain (hemorrhage).
		Nimodipine is also used sometimes to treat migraine headaches.
		Nimodipine should be taken on an empty stomach, either 1 hour before a meal or 2 hours after a meal.
	www.nlm.nih.gov /medlineplus/druginfo/medmaster/a689010.html (667 words)

	Nimodipine - Wikipedia, the free encyclopedia
		Nimodipine (marketed by Bayer as Nimotop®) is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure.
		Because it has some selectivity for cerebral vasculature, nimodipine's main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed).
		Nimodipine is associated with low blood pressure, flushing and sweating, edema, nausea and other gastrointestinal problems.
	en.wikipedia.org /wiki/Nimodipine (376 words)

	Nimodipine (Site not responding. Last check: 2007-11-01)
		Nimodipine also has shown efficacy in the prophylaxis of migraine.† Nimodipine was approved by the FDA in December 1988.
		Although the exact mechanism is unknown, it is believed that nimodipine inhibits this influx by binding to specific receptors on the cell membrane in or near the calcium channel, which causes a conformational change in the channel, making it unavailable for opening.
		This activity is believed to be due to nimodipine's lipophilic properties, and it gives rise to its use in patients with SAH to prevent neurologic deficits that occur during or following cerebral vasospasm and in patients with migraine.† Arteriographic evidence, however, does not exist to show that it prevents or relieves vasospasm of cerebral arteries.
	www.argenmex.com.ar /nimodipi.htm (392 words)

	Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review) (Site not responding. Last check: 2007-11-01)
		Nimodipine is well tolerated with a low rate of adverse effects similar to that associated with placebo.
		To assess the clinical efficacy of nimodipine for the manifestations of dementia, in unclassified disease and in the major subtypes - Alzheimer's disease, cerebrovascular disease, and mixed Alzheimer's and cerebrovascular disease.
		Nimodipine can be of some benefit in the treatment of patients with features of dementia due to unclassified disease or to Alzheimer's disease, cerebrovascular disease, or mixed Alzheimer's and cerebrovascular disease.
	www.update-software.com /abstracts/ab000147.htm (747 words)

Try your search on: Qwika (all wikis)